Arcus Biosciences Inc.
RCUS | NYSE
$26.55
+$0.60 (+2.31%)
Sep 22, 2026, 1:47 PM ET · Market open
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 | FY 2021 Dec 30, 2021 | FY 2020 Dec 30, 2020 |
|---|---|---|---|---|---|---|
Net Income | -353M | -283M | -307M | -267M | 52.83M | -122.86M |
Depreciation & Amortization | 10M | 10M | 8M | 14M | 3.84M | 4.19M |
Stock-Based Compensation | 60M | 76M | 73M | 65M | 55M | 22M |
Other Working Capital | -227M | -9M | -85M | -89M | -367.88M | 178.38M |
Other Non-Cash Items | -5M | 5M | -9M | 68M | 3.47M | -46K |
Deferred Income Tax | n/a | n/a | n/a | n/a | 4.77M | n/a |
Change in Working Capital | -194M | 22M | -71M | 623M | -375.62M | 208.06M |
Operating Cash Flow | -482M | -170M | -306M | 438M | -256.17M | 111.17M |
Capital Expenditures | -2M | -6M | -24M | -6M | -26.08M | -3.06M |
Cash Acquisitions | n/a | n/a | n/a | n/a | -22M | 431M |
Purchase of Investments | -1.08B | -1.04B | -788M | -1.24B | -718.87M | -739.66M |
Sales Maturities Of Investments | 1.14B | 965M | 1.01B | 837M | 741.08M | 308.35M |
Other Investing Acitivies | n/a | n/a | n/a | -3M | 22M | -431M |
Investing Cash Flow | 66M | -84M | 194M | -413M | -3.87M | -434.37M |
Debt Repayment | 49M | 47M | n/a | 10M | 5M | n/a |
Common Stock Repurchased | n/a | n/a | n/a | n/a | -6K | -54K |
Dividend Paid | n/a | n/a | n/a | n/a | n/a | n/a |
Other Financial Acitivies | n/a | 2M | 8M | n/a | 12.34M | 4.68M |
Financial Cash Flow | 488M | 277M | 33M | 33M | 237.34M | 438.68M |
Net Cash Flow | 72M | 23M | -79M | 58.09M | -22.7M | 115.48M |
Free Cash Flow | -484M | -176M | -330M | 432M | -282.25M | 108.12M |
Adj. Free Cash Flow | -544M | -252M | -403M | 367M | -337.25M | 86.12M |
Maintenance CapEx | -2M | n/a | -21.35M | -6M | n/a | n/a |
Growth CapEx | n/a | -6M | -2.65M | n/a | -26.08M | -3.06M |
Owner Earnings | -484M | -170M | -327.35M | 432M | -256.17M | 111.17M |
Add to Watchlist
Select watchlists to add or remove RCUS